- Home
- AGMH vs LIPO Comparison
AGMH vs LIPO Comparison
Compare AGMH & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- LIPO
- Stock Information
- Founded
- AGMH 2015
- LIPO 2005
- Country
- AGMH Hong Kong
- LIPO United States
- Employees
- AGMH N/A
- LIPO N/A
- Industry
- AGMH EDP Services
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- LIPO Health Care
- Exchange
- AGMH Nasdaq
- LIPO Nasdaq
- Market Cap
- AGMH 3.5M
- LIPO 3.1M
- IPO Year
- AGMH 2018
- LIPO 2022
- Fundamental
- Price
- AGMH $3.11
- LIPO $2.99
- Analyst Decision
- AGMH
- LIPO
- Analyst Count
- AGMH 0
- LIPO 0
- Target Price
- AGMH N/A
- LIPO N/A
- AVG Volume (30 Days)
- AGMH 857.7K
- LIPO 39.2K
- Earning Date
- AGMH 06-18-2025
- LIPO 05-14-2025
- Dividend Yield
- AGMH N/A
- LIPO N/A
- EPS Growth
- AGMH N/A
- LIPO N/A
- EPS
- AGMH 6.43
- LIPO N/A
- Revenue
- AGMH $32,044,575.00
- LIPO $519,866.00
- Revenue This Year
- AGMH N/A
- LIPO N/A
- Revenue Next Year
- AGMH N/A
- LIPO N/A
- P/E Ratio
- AGMH $0.44
- LIPO N/A
- Revenue Growth
- AGMH N/A
- LIPO 8.88
- 52 Week Low
- AGMH $1.09
- LIPO $1.97
- 52 Week High
- AGMH $109.50
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- AGMH 44.31
- LIPO 58.50
- Support Level
- AGMH $2.11
- LIPO $2.75
- Resistance Level
- AGMH $4.93
- LIPO $3.17
- Average True Range (ATR)
- AGMH 0.67
- LIPO 0.29
- MACD
- AGMH 0.00
- LIPO 0.02
- Stochastic Oscillator
- AGMH 35.46
- LIPO 81.05
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.